GSK (NYSE:GSK) Upgraded at Bank of America

Bank of America upgraded shares of GSK (NYSE:GSK) from an underperform rating to a neutral rating in a research report report published on Tuesday morning, Marketbeat.com reports.

A number of other analysts have also weighed in on the stock. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research report on Monday, October 27th. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Weiss Ratings restated a “buy (b)” rating on shares of GSK in a report on Thursday, November 20th. Finally, Cfra set a $53.00 target price on GSK in a research note on Thursday, October 30th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $44.13.

GSK Stock Up 1.0%

Shares of GSK opened at $48.03 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The business has a fifty day moving average of $44.83 and a 200 day moving average of $41.03. The company has a market cap of $97.51 billion, a PE ratio of 13.57, a P/E/G ratio of 1.90 and a beta of 0.50. GSK has a 52-week low of $31.72 and a 52-week high of $48.69.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.22. The business had revenue of $11.35 billion for the quarter, compared to the consensus estimate of $8.21 billion. GSK had a net margin of 17.16% and a return on equity of 51.07%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. On average, sell-side analysts expect that GSK will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Friday, November 14th will be issued a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a yield of 3.5%. The ex-dividend date is Friday, November 14th. GSK’s dividend payout ratio (DPR) is presently 46.05%.

Hedge Funds Weigh In On GSK

A number of hedge funds and other institutional investors have recently made changes to their positions in GSK. Twin Peaks Wealth Advisors LLC bought a new stake in shares of GSK in the second quarter valued at about $25,000. HHM Wealth Advisors LLC increased its position in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 460 shares during the period. Costello Asset Management INC bought a new stake in shares of GSK in the 1st quarter valued at about $31,000. CNB Bank purchased a new stake in shares of GSK in the 3rd quarter worth approximately $31,000. Finally, SOA Wealth Advisors LLC. boosted its stake in shares of GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 605 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.